Document:

kodk-ex1024_19.htm

Execution Copy

 

Exhibit (10.24)

 

EASTMAN KODAK COMPANY

2013 OMNIBUS INCENTIVE PLAN

Award Agreement

This “Award Agreement” evidences an award of Nonqualified Stock Options (the “Options”) by the Company under the Eastman Kodak Company 2013 Omnibus Incentive Plan, as amended effective May 22, 2018 and as it may be further amended (the “Plan”), as indicated below.  The Options are subject to all other terms set forth in the Plan and this Award Agreement.  Capitalized terms not defined in this Award Agreement have the meanings given to them in the Plan.  

Name of Grantee:James V. Continenza

Grant Date:February 20, 2019

Number of Options:1,150,000 with an Option Price of $3.03

Vesting Schedule:

		
	
Vesting Date
	
Percentage Vesting

	
February 20, 2019
	
50%

	
May 20, 2019
	
12.5%

	
August 20, 2019
	
12.5%

	
November 20, 2019
	
12.5%

	
February 20, 2020
	
12.5%

 

Vesting:

The Vesting Schedule for the Options awarded hereunder is set forth above under “Vesting Schedule.”  The Options will only vest if the Grantee is continuously employed by the Company or any of its Affiliates from the Grant Date through the applicable Vesting Date, and except as otherwise provided by this Award Agreement or determined by the Committee, any unvested Options will be forfeited upon any termination of employment.  

Notwithstanding the prior sentence, if the Grantee has an employment agreement with the Company that provides for continued or accelerated vesting upon certain qualifying terminations, the terms and conditions in that employment agreement will control.

1

 

Execution Copy

Notwithstanding anything in this Award Agreement, the Plan, or in the Grantee’s employment agreement with the Company to the contrary, upon the consummation of a Change of Control, any outstanding Options that have not become vested pursuant to the foregoing Vesting Schedule shall immediately become vested; provided that the Grantee remains continuously employed by the Company through and including the consummation of such Change of Control.

Upon termination of employment, vested Options shall remain exercisable until they expire as set forth below under “Expiration Date.”

Exercise:

No Option will be exercisable prior to the date on which it vests.  Upon Vesting, the Options will allow the purchase of Shares at the Option Price noted above.  Each Option provides for the ability to purchase a single Share.  

Subject to the “Withholding” provision below, the Options shall be exercised by written notice or by any other method permitted by the Committee stating the number of Options to be exercised, with payment of the aggregate Option Price for the number of Options exercised.

The aggregate Option Price for the Shares as to which an Option is exercised shall be paid to the Company in full at the time of exercise at the election of the Grantee:

	
 
	
(i)
	
in cash or its equivalent (e.g., by cashier’s check); 

	
 
	
(ii)
	
to the extent permitted by the Committee, in Shares previously owned by the Grantee having a Fair Market Value equal to the aggregate Option Price for the Shares being purchased and satisfying such other requirements as may be imposed by the Committee, 

	
 
	
(iii)
	
any combination of the foregoing; or 

	
 
	
(iv)
	
in consideration received by the Company under a cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan.

Under no circumstances will fractional Shares be issued; if the Grantee elects to pay the Option Price for the Shares using Shares already owned by him, or Shares to be received from his exercise of this Option and such payment involves a fraction of a Share, the remaining fraction of such Share shall be redeemed by the Company and the Company shall pay the Grantee the Fair Market Value of such fractional Share in cash in lieu of issuing such fractional Share. 

Expiration Date:

Each Option will expire at the close of business on the day immediately prior to the seventh (7th) anniversary of the Grant Date, unless sooner forfeited in accordance with the terms and conditions of this Award Agreement or the Plan.

2

 

Execution Copy

Withholding:

Pursuant to Section 16.4 of the Plan, the Company shall have the power and the right to deduct or withhold (or cause to be deducted or withheld) from any amount deliverable under the Options or otherwise (including Shares otherwise deliverable), or require the Grantee to remit to the Company, the minimum statutory amount to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulation to be withheld with respect to any taxable event arising in connection with the Options. 

Subject to the Company’s automatic withholding right set out above, the Grantee may elect to satisfy the withholding requirement, in whole or in part:

	
 
	
(i) 
	
by having the Company withhold Shares; or 

	
 
	
(ii)
	
through an independent broker-dealer arrangement to sell a sufficient number of Shares;

in each case, having a Fair Market Value on the date the tax is to be determined equal to the minimum tax required to be withheld.

Grantee Rights:

The Grantee will not have any of the rights of a shareholder with respect to the Shares underlying or covered by the Options, whether or not vested, until such Shares are actually issued and delivered to the Grantee.

Change of Control:

Upon the occurrence of a Change of Control, the Committee may, but shall not be required, to make one or more of the adjustments set forth in Section 14.2 of the Plan to the Options if and to the extent that the Options are outstanding at the time of the Change of Control.  

Transferability:

Except as otherwise provided by the Plan, the Options are not in any manner subject to alteration, anticipation, sale, transfer, assignment, pledge or encumbrance.

No Right to Continued Employment:

The Grantee’s receipt of the Options does not give the Grantee a right to remain in the employment of the Company.

Data Privacy:

By accepting the Options, the Grantee agrees that any data, including the Grantee’s personal data, may be exchanged among the Company and its Affiliates to the extent the Company determines necessary or advisable to administer the Plan and the Options, as well as with any third-party engaged by the Company to administer the Plan and the Options granted under the Plan.

3

 

Execution Copy

Amendment:

Pursuant to Section 15.2 of the Plan, the Committee may from time to time amend this Award Agreement; provided, however, no amendment shall materially adversely impair the rights of the Grantee under this Award Agreement without the Grantee’s consent.

Miscellaneous:

The Options described in this Award Agreement are intended to be exempt from Section 409A under the stock rights exemption thereto, and the Plan and this Award Agreement shall be interpreted and administered consistent with such intention, and in accordance with Eastman Kodak Company’s Policy Regarding Section 409A Compliance.  The Company may unilaterally amend this Award Agreement for purposes of exemption from or compliance with Section 409A if, in its sole discretion, the Company determines that such amendment would not have a material adverse effect with respect to the Grantee’s rights under this Award Agreement.  Notwithstanding the foregoing, no person connected with the Plan or the Options in any capacity, including, but not limited to, the Company and its directors, officers, agents and employees makes any representation, commitment, or guarantee that any tax treatment will be applicable with respect to the Options or payments made under this Award Agreement, or that such tax treatment will apply to or be available to the Grantee.

The Options (either at the time of vesting or exercise, or otherwise) will not be includible as compensation or earnings for purposes of any benefit or compensation plan offered by the Company or its Affiliates.

The obligations of the Company pursuant hereto are subject to compliance with all applicable governmental laws, regulations, rules and administrative actions, including, but not limited to, the Securities Act of 1933, as amended, and the Exchange Act, and all rules promulgated thereunder.  In order to avoid any violations, the Committee may, at any time and from time to time, impose additional restrictions upon the Options.

The Option is subject to the Plan and any interpretations by the Committee under the Plan, which are hereby incorporated into this Award Agreement by reference and made a part hereof.  In the event of any conflict between this Award Agreement and the Plan, the terms of the Plan shall control.

This Award Agreement, together with the Plan and the employment agreement between the Company and the Grantee, contains the entire agreement between the Grantee and the Company with respect to the subject matter of this Award Agreement.

By accepting the Options, the Grantee agrees to be subject to the terms and conditions of the Plan and this Award Agreement.

*****

4

 

Execution Copy

EASTMAN KODAK COMPANY

2013 OMNIBUS INCENTIVE PLAN

Award Agreement

This “Award Agreement” evidences an award of Nonqualified Stock Options (the “Options”) by the Company under the Eastman Kodak Company 2013 Omnibus Incentive Plan, as amended effective May 22, 2018 and as it may be further amended (the “Plan”), as indicated below.  The Options are subject to all other terms set forth in the Plan and this Award Agreement.  Capitalized terms not defined in this Award Agreement have the meanings given to them in the Plan.  

Name of Grantee:James V. Continenza

Grant Date:February 20, 2019

Number of Options:350,000 with an Option Price of $4.53

Vesting Schedule:

		
	
Vesting Date
	
Percentage Vesting

	
February 20, 2019
	
50%

	
May 20, 2019
	
12.5%

	
August 20, 2019
	
12.5%

	
November 20, 2019
	
12.5%

	
February 20, 2020
	
12.5%

 

Vesting:

The Vesting Schedule for the Options awarded hereunder is set forth above under “Vesting Schedule.”  The Options will only vest if the Grantee is continuously employed by the Company or any of its Affiliates from the Grant Date through the applicable Vesting Date, and except as otherwise provided by this Award Agreement or determined by the Committee, any unvested Options will be forfeited upon any termination of employment.  

Notwithstanding the prior sentence, if the Grantee has an employment agreement with the Company that provides for continued or accelerated vesting upon certain qualifying terminations, the terms and conditions in that employment agreement will control.

Notwithstanding anything in this Award Agreement, the Plan, or in the Grantee’s employment agreement with the Company to the contrary, upon the consummation of a Change of Control, any outstanding Options that have not become vested pursuant to the foregoing Vesting Schedule shall immediately become vested; provided that the Grantee remains continuously employed by the Company through and including the consummation of such Change of Control.

Upon termination of employment, vested Options shall remain exercisable until they expire as set forth below under “Expiration Date.”

5

 

Execution Copy

Exercise:

No Option will be exercisable prior to the date on which it vests.  Upon Vesting, the Options will allow the purchase of Shares at the Option Price noted above.  Each Option provides for the ability to purchase a single Share.  

Subject to the “Withholding” provision below, the Options shall be exercised by written notice or by any other method permitted by the Committee stating the number of Options to be exercised, with payment of the aggregate Option Price for the number of Options exercised.

The aggregate Option Price for the Shares as to which an Option is exercised shall be paid to the Company in full at the time of exercise at the election of the Grantee:

	
 
	
(i)
	
in cash or its equivalent (e.g., by cashier’s check); 

	
 
	
(ii)
	
to the extent permitted by the Committee, in Shares previously owned by the Grantee having a Fair Market Value equal to the aggregate Option Price for the Shares being purchased and satisfying such other requirements as may be imposed by the Committee, 

	
 
	
(iii)
	
any combination of the foregoing; or 

	
 
	
(iv)
	
in consideration received by the Company under a cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan.

Under no circumstances will fractional Shares be issued; if the Grantee elects to pay the Option Price for the Shares using Shares already owned by him, or Shares to be received from his exercise of this Option and such payment involves a fraction of a Share, the remaining fraction of such Share shall be redeemed by the Company and the Company shall pay the Grantee the Fair Market Value of such fractional Share in cash in lieu of issuing such fractional Share. 

Expiration Date:

Each Option will expire at the close of business on the day immediately prior to the seventh (7th) anniversary of the Grant Date, unless sooner forfeited in accordance with the terms and conditions of this Award Agreement or the Plan.

Withholding:

Pursuant to Section 16.4 of the Plan, the Company shall have the power and the right to deduct or withhold (or cause to be deducted or withheld) from any amount deliverable under the Options or otherwise (including Shares otherwise deliverable), or require the Grantee to remit to the Company, the minimum statutory amount to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulation to be withheld with respect to any taxable event arising in connection with the Options. 

6

 

Execution Copy

Subject to the Company’s automatic withholding right set out above, the Grantee may elect to satisfy the withholding requirement, in whole or in part:

	
 
	
(i) 
	
by having the Company withhold Shares; or 

	
 
	
(ii)
	
through an independent broker-dealer arrangement to sell a sufficient number of Shares;

in each case, having a Fair Market Value on the date the tax is to be determined equal to the minimum tax required to be withheld.

Grantee Rights:

The Grantee will not have any of the rights of a shareholder with respect to the Shares underlying or covered by the Options, whether or not vested, until such Shares are actually issued and delivered to the Grantee.

Change of Control:

Upon the occurrence of a Change of Control, the Committee may, but shall not be required, to make one or more of the adjustments set forth in Section 14.2 of the Plan to the Options if and to the extent that the Options are outstanding at the time of the Change of Control.  

Transferability:

Except as otherwise provided by the Plan, the Options are not in any manner subject to alteration, anticipation, sale, transfer, assignment, pledge or encumbrance.

No Right to Continued Employment:

The Grantee’s receipt of the Options does not give the Grantee a right to remain in the employment of the Company.

Data Privacy:

By accepting the Options, the Grantee agrees that any data, including the Grantee’s personal data, may be exchanged among the Company and its Affiliates to the extent the Company determines necessary or advisable to administer the Plan and the Options, as well as with any third-party engaged by the Company to administer the Plan and the Options granted under the Plan.

Amendment:

Pursuant to Section 15.2 of the Plan, the Committee may from time to time amend this Award Agreement; provided, however, no amendment shall materially adversely impair the rights of the Grantee under this Award Agreement without the Grantee’s consent.

7

 

Execution Copy

Miscellaneous:

The Options described in this Award Agreement are intended to be exempt from Section 409A under the stock rights exemption thereto, and the Plan and this Award Agreement shall be interpreted and administered consistent with such intention, and in accordance with Eastman Kodak Company’s Policy Regarding Section 409A Compliance.  The Company may unilaterally amend this Award Agreement for purposes of exemption from or compliance with Section 409A if, in its sole discretion, the Company determines that such amendment would not have a material adverse effect with respect to the Grantee’s rights under this Award Agreement.  Notwithstanding the foregoing, no person connected with the Plan or the Options in any capacity, including, but not limited to, the Company and its directors, officers, agents and employees makes any representation, commitment, or guarantee that any tax treatment will be applicable with respect to the Options or payments made under this Award Agreement, or that such tax treatment will apply to or be available to the Grantee.

The Options (either at the time of vesting or exercise, or otherwise) will not be includible as compensation or earnings for purposes of any benefit or compensation plan offered by the Company or its Affiliates.

The obligations of the Company pursuant hereto are subject to compliance with all applicable governmental laws, regulations, rules and administrative actions, including, but not limited to, the Securities Act of 1933, as amended, and the Exchange Act, and all rules promulgated thereunder.  In order to avoid any violations, the Committee may, at any time and from time to time, impose additional restrictions upon the Options.

The Option is subject to the Plan and any interpretations by the Committee under the Plan, which are hereby incorporated into this Award Agreement by reference and made a part hereof.  In the event of any conflict between this Award Agreement and the Plan, the terms of the Plan shall control.

This Award Agreement, together with the Plan and the employment agreement between the Company and the Grantee, contains the entire agreement between the Grantee and the Company with respect to the subject matter of this Award Agreement.

By accepting the Options, the Grantee agrees to be subject to the terms and conditions of the Plan and this Award Agreement.

*****

8

 

Execution Copy

EASTMAN KODAK COMPANY

2013 OMNIBUS INCENTIVE PLAN

Award Agreement

This “Award Agreement” evidences an award of Nonqualified Stock Options (the “Options”) by the Company under the Eastman Kodak Company 2013 Omnibus Incentive Plan, as amended effective May 22, 2018 and as it may be further amended (the “Plan”), as indicated below.  The Options are subject to all other terms set forth in the Plan and this Award Agreement.  Capitalized terms not defined in this Award Agreement have the meanings given to them in the Plan.  

Name of Grantee:James V. Continenza

Grant Date:February 20, 2019

Number of Options:350,000 with an Option Price of $6.03

Vesting Schedule:

		
	
Vesting Date
	
Percentage Vesting

	
February 20, 2019
	
50%

	
May 20, 2019
	
12.5%

	
August 20, 2019
	
12.5%

	
November 20, 2019
	
12.5%

	
February 20, 2020
	
12.5%

 

Vesting:

The Vesting Schedule for the Options awarded hereunder is set forth above under “Vesting Schedule.”  The Options will only vest if the Grantee is continuously employed by the Company or any of its Affiliates from the Grant Date through the applicable Vesting Date, and except as otherwise provided by this Award Agreement or determined by the Committee, any unvested Options will be forfeited upon any termination of employment.  

Notwithstanding the prior sentence, if the Grantee has an employment agreement with the Company that provides for continued or accelerated vesting upon certain qualifying terminations, the terms and conditions in that employment agreement will control.

Notwithstanding anything in this Award Agreement, the Plan, or in the Grantee’s employment agreement with the Company to the contrary, upon the consummation of a Change of Control, any outstanding Options that have not become vested pursuant to the foregoing Vesting Schedule shall immediately become vested; provided that the Grantee remains continuously employed by the Company through and including the consummation of such Change of Control.

Upon termination of employment, vested Options shall remain exercisable until they expire as set forth below under “Expiration Date.”

9

 

Execution Copy

Exercise:

No Option will be exercisable prior to the date on which it vests.  Upon Vesting, the Options will allow the purchase of Shares at the Option Price noted above.  Each Option provides for the ability to purchase a single Share.  

Subject to the “Withholding” provision below, the Options shall be exercised by written notice or by any other method permitted by the Committee stating the number of Options to be exercised, with payment of the aggregate Option Price for the number of Options exercised.

The aggregate Option Price for the Shares as to which an Option is exercised shall be paid to the Company in full at the time of exercise at the election of the Grantee:

	
 
	
(i)
	
in cash or its equivalent (e.g., by cashier’s check); 

	
 
	
(ii)
	
to the extent permitted by the Committee, in Shares previously owned by the Grantee having a Fair Market Value equal to the aggregate Option Price for the Shares being purchased and satisfying such other requirements as may be imposed by the Committee, 

	
 
	
(iii)
	
any combination of the foregoing; or 

	
 
	
(iv)
	
in consideration received by the Company under a cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan.

Under no circumstances will fractional Shares be issued; if the Grantee elects to pay the Option Price for the Shares using Shares already owned by him, or Shares to be received from his exercise of this Option and such payment involves a fraction of a Share, the remaining fraction of such Share shall be redeemed by the Company and the Company shall pay the Grantee the Fair Market Value of such fractional Share in cash in lieu of issuing such fractional Share. 

Expiration Date:

Each Option will expire at the close of business on the day immediately prior to the seventh (7th) anniversary of the Grant Date, unless sooner forfeited in accordance with the terms and conditions of this Award Agreement or the Plan.

Withholding:

Pursuant to Section 16.4 of the Plan, the Company shall have the power and the right to deduct or withhold (or cause to be deducted or withheld) from any amount deliverable under the Options or otherwise (including Shares otherwise deliverable), or require the Grantee to remit to the Company, the minimum statutory amount to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulation to be withheld with respect to any taxable event arising in connection with the Options. 

10

 

Execution Copy

Subject to the Company’s automatic withholding right set out above, the Grantee may elect to satisfy the withholding requirement, in whole or in part:

	
 
	
(i) 
	
by having the Company withhold Shares; or 

	
 
	
(ii)
	
through an independent broker-dealer arrangement to sell a sufficient number of Shares;

in each case, having a Fair Market Value on the date the tax is to be determined equal to the minimum tax required to be withheld.

Grantee Rights:

The Grantee will not have any of the rights of a shareholder with respect to the Shares underlying or covered by the Options, whether or not vested, until such Shares are actually issued and delivered to the Grantee.

Change of Control:

Upon the occurrence of a Change of Control, the Committee may, but shall not be required, to make one or more of the adjustments set forth in Section 14.2 of the Plan to the Options if and to the extent that the Options are outstanding at the time of the Change of Control.  

Transferability:

Except as otherwise provided by the Plan, the Options are not in any manner subject to alteration, anticipation, sale, transfer, assignment, pledge or encumbrance.

No Right to Continued Employment:

The Grantee’s receipt of the Options does not give the Grantee a right to remain in the employment of the Company.

Data Privacy:

By accepting the Options, the Grantee agrees that any data, including the Grantee’s personal data, may be exchanged among the Company and its Affiliates to the extent the Company determines necessary or advisable to administer the Plan and the Options, as well as with any third-party engaged by the Company to administer the Plan and the Options granted under the Plan.

Amendment:

Pursuant to Section 15.2 of the Plan, the Committee may from time to time amend this Award Agreement; provided, however, no amendment shall materially adversely impair the rights of the Grantee under this Award Agreement without the Grantee’s consent.

11

 

Execution Copy

Miscellaneous:

The Options described in this Award Agreement are intended to be exempt from Section 409A under the stock rights exemption thereto, and the Plan and this Award Agreement shall be interpreted and administered consistent with such intention, and in accordance with Eastman Kodak Company’s Policy Regarding Section 409A Compliance.  The Company may unilaterally amend this Award Agreement for purposes of exemption from or compliance with Section 409A if, in its sole discretion, the Company determines that such amendment would not have a material adverse effect with respect to the Grantee’s rights under this Award Agreement.  Notwithstanding the foregoing, no person connected with the Plan or the Options in any capacity, including, but not limited to, the Company and its directors, officers, agents and employees makes any representation, commitment, or guarantee that any tax treatment will be applicable with respect to the Options or payments made under this Award Agreement, or that such tax treatment will apply to or be available to the Grantee.

The Options (either at the time of vesting or exercise, or otherwise) will not be includible as compensation or earnings for purposes of any benefit or compensation plan offered by the Company or its Affiliates.

The obligations of the Company pursuant hereto are subject to compliance with all applicable governmental laws, regulations, rules and administrative actions, including, but not limited to, the Securities Act of 1933, as amended, and the Exchange Act, and all rules promulgated thereunder.  In order to avoid any violations, the Committee may, at any time and from time to time, impose additional restrictions upon the Options.

The Option is subject to the Plan and any interpretations by the Committee under the Plan, which are hereby incorporated into this Award Agreement by reference and made a part hereof.  In the event of any conflict between this Award Agreement and the Plan, the terms of the Plan shall control.

This Award Agreement, together with the Plan and the employment agreement between the Company and the Grantee, contains the entire agreement between the Grantee and the Company with respect to the subject matter of this Award Agreement.

By accepting the Options, the Grantee agrees to be subject to the terms and conditions of the Plan and this Award Agreement.

*****

 

12

 

Execution Copy

EASTMAN KODAK COMPANY

2013 OMNIBUS INCENTIVE PLAN

Award Agreement

This “Award Agreement” evidences an award of Nonqualified Stock Options (the “Options”) by the Company under the Eastman Kodak Company 2013 Omnibus Incentive Plan, as amended effective May 22, 2018 and as it may be further amended (the “Plan”), as indicated below.  The Options are subject to all other terms set forth in the Plan and this Award Agreement.  Capitalized terms not defined in this Award Agreement have the meanings given to them in the Plan.  

Name of Grantee:James V. Continenza

Grant Date:February 20, 2019

Number of Options:200,000 with an Option Price of $12.00

Vesting Schedule:

		
	
Vesting Date
	
Percentage Vesting

	
February 20, 2019
	
50%

	
May 20, 2019
	
12.5%

	
August 20, 2019
	
12.5%

	
November 20, 2019
	
12.5%

	
February 20, 2020
	
12.5%

 

Vesting:

The Vesting Schedule for the Options awarded hereunder is set forth above under “Vesting Schedule.”  The Options will only vest if the Grantee is continuously employed by the Company or any of its Affiliates from the Grant Date through the applicable Vesting Date, and except as otherwise provided by this Award Agreement or determined by the Committee, any unvested Options will be forfeited upon any termination of employment.  

Notwithstanding the prior sentence, if the Grantee has an employment agreement with the Company that provides for continued or accelerated vesting upon certain qualifying terminations, the terms and conditions in that employment agreement will control.

Notwithstanding anything in this Award Agreement, the Plan, or in the Grantee’s employment agreement with the Company to the contrary, upon the consummation of a Change of Control, any outstanding Options that have not become vested pursuant to the foregoing Vesting Schedule shall immediately become vested; provided that the Grantee remains continuously employed by the Company through and including the consummation of such Change of Control.

Upon termination of employment, vested Options shall remain exercisable until they expire as set forth below under “Expiration Date.”

13

 

Execution Copy

Exercise:

No Option will be exercisable prior to the date on which it vests.  Upon Vesting, the Options will allow the purchase of Shares at the Option Price noted above.  Each Option provides for the ability to purchase a single Share.  

Subject to the “Withholding” provision below, the Options shall be exercised by written notice or by any other method permitted by the Committee stating the number of Options to be exercised, with payment of the aggregate Option Price for the number of Options exercised.

The aggregate Option Price for the Shares as to which an Option is exercised shall be paid to the Company in full at the time of exercise at the election of the Grantee:

	
 
	
(i)
	
in cash or its equivalent (e.g., by cashier’s check); 

	
 
	
(ii)
	
to the extent permitted by the Committee, in Shares previously owned by the Grantee having a Fair Market Value equal to the aggregate Option Price for the Shares being purchased and satisfying such other requirements as may be imposed by the Committee, 

	
 
	
(iii)
	
any combination of the foregoing; or 

	
 
	
(iv)
	
in consideration received by the Company under a cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan.

Under no circumstances will fractional Shares be issued; if the Grantee elects to pay the Option Price for the Shares using Shares already owned by him, or Shares to be received from his exercise of this Option and such payment involves a fraction of a Share, the remaining fraction of such Share shall be redeemed by the Company and the Company shall pay the Grantee the Fair Market Value of such fractional Share in cash in lieu of issuing such fractional Share. 

Expiration Date:

Each Option will expire at the close of business on the day immediately prior to the seventh (7th) anniversary of the Grant Date, unless sooner forfeited in accordance with the terms and conditions of this Award Agreement or the Plan.

Withholding:

Pursuant to Section 16.4 of the Plan, the Company shall have the power and the right to deduct or withhold (or cause to be deducted or withheld) from any amount deliverable under the Options or otherwise (including Shares otherwise deliverable), or require the Grantee to remit to the Company, the minimum statutory amount to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulation to be withheld with respect to any taxable event arising in connection with the Options. 

14

 

Execution Copy

Subject to the Company’s automatic withholding right set out above, the Grantee may elect to satisfy the withholding requirement, in whole or in part:

	
 
	
(i) 
	
by having the Company withhold Shares; or 

	
 
	
(ii)
	
through an independent broker-dealer arrangement to sell a sufficient number of Shares;

in each case, having a Fair Market Value on the date the tax is to be determined equal to the minimum tax required to be withheld.

Grantee Rights:

The Grantee will not have any of the rights of a shareholder with respect to the Shares underlying or covered by the Options, whether or not vested, until such Shares are actually issued and delivered to the Grantee.

Change of Control:

Upon the occurrence of a Change of Control, the Committee may, but shall not be required, to make one or more of the adjustments set forth in Section 14.2 of the Plan to the Options if and to the extent that the Options are outstanding at the time of the Change of Control.  

Transferability:

Except as otherwise provided by the Plan, the Options are not in any manner subject to alteration, anticipation, sale, transfer, assignment, pledge or encumbrance.

No Right to Continued Employment:

The Grantee’s receipt of the Options does not give the Grantee a right to remain in the employment of the Company.

Data Privacy:

By accepting the Options, the Grantee agrees that any data, including the Grantee’s personal data, may be exchanged among the Company and its Affiliates to the extent the Company determines necessary or advisable to administer the Plan and the Options, as well as with any third-party engaged by the Company to administer the Plan and the Options granted under the Plan.

Amendment:

Pursuant to Section 15.2 of the Plan, the Committee may from time to time amend this Award Agreement; provided, however, no amendment shall materially adversely impair the rights of the Grantee under this Award Agreement without the Grantee’s consent.

15

 

Execution Copy

Miscellaneous:

The Options described in this Award Agreement are intended to be exempt from Section 409A under the stock rights exemption thereto, and the Plan and this Award Agreement shall be interpreted and administered consistent with such intention, and in accordance with Eastman Kodak Company’s Policy Regarding Section 409A Compliance.  The Company may unilaterally amend this Award Agreement for purposes of exemption from or compliance with Section 409A if, in its sole discretion, the Company determines that such amendment would not have a material adverse effect with respect to the Grantee’s rights under this Award Agreement.  Notwithstanding the foregoing, no person connected with the Plan or the Options in any capacity, including, but not limited to, the Company and its directors, officers, agents and employees makes any representation, commitment, or guarantee that any tax treatment will be applicable with respect to the Options or payments made under this Award Agreement, or that such tax treatment will apply to or be available to the Grantee.

The Options (either at the time of vesting or exercise, or otherwise) will not be includible as compensation or earnings for purposes of any benefit or compensation plan offered by the Company or its Affiliates.

The obligations of the Company pursuant hereto are subject to compliance with all applicable governmental laws, regulations, rules and administrative actions, including, but not limited to, the Securities Act of 1933, as amended, and the Exchange Act, and all rules promulgated thereunder.  In order to avoid any violations, the Committee may, at any time and from time to time, impose additional restrictions upon the Options.

The Option is subject to the Plan and any interpretations by the Committee under the Plan, which are hereby incorporated into this Award Agreement by reference and made a part hereof.  In the event of any conflict between this Award Agreement and the Plan, the terms of the Plan shall control.

This Award Agreement, together with the Plan and the employment agreement between the Company and the Grantee, contains the entire agreement between the Grantee and the Company with respect to the subject matter of this Award Agreement.

By accepting the Options, the Grantee agrees to be subject to the terms and conditions of the Plan and this Award Agreement.

*****

 

 

 

 

 

16SEPARATION
AGREEMENT

 

This
Separation Agreement (“Separation Agreement”) is entered into by and between Kristine Mecham (“Executive”)
and OncoCyte Corporation. (the “Company”) and confirms the agreement that has been reached with Executive in connection
with Executive’s separation from the Company.

 

1.
Termination of Employment.
Executive’s separation shall be effective as of January 22, 2019 (the “Separation Date”) and as of such date
Executive shall cease to be employed by the Company and by each and every subsidiary of the Company in any capacity. Executive
further agrees to execute promptly upon request by the Company any additional documents necessary to effectuate the provisions
of this Section 1. It is agreed that Executive’s separation constitutes a transition mutually agreed between the parties
and this Agreement supersedes the Employment Agreement, dated August 1, 2015 and the Sabbatical Agreement, as amended, dated June
7, 2018, between the parties (the “Employment Agreement”), except for those provisions of the Employment Agreement
that are expressly referenced in, or incorporated by reference into, this Agreement. Any capitalized terms not defined in this
Separation Agreement shall have the meaning ascribed to such terms in the Employment Agreement.

 

2.
Separation Agreement Payments
and Benefits. Provided that Executive (i)
executes this Separation Agreement not later than the twenty-first day after it is furnished to Executive (and not earlier than
the Separation Date), (ii) does not exercise the right of revocation set forth in Section 12, and (iii) otherwise complies in
all material respects with all of the terms and conditions of this Separation Agreement, the Company shall pay or provide Executive
with the following:

 

(a)
Executive will receive the amount of $114,000.00
dollars, which represents Executive’s Base Salary for six (6) months, to be paid in two equal installments. The first installment
will be paid in the first payroll after the revocation period has passed, and the second installment will be paid on the March
15, 2019 payroll; provided the Separation Agreement has not been revoked as provided in Section 12. Normal and customary payroll
withholdings and deductions shall be made from such payment, and the amount will be reported for tax purposes as required by law.
In connection with this payment, the Company shall issue a Form W-2 in the regular course of business.

 

(b)
Executive will receive any accrued but unpaid
bonus. Normal and customary payroll withholdings and deductions shall be made from such payment, and the amount will be reported
for tax purposes as required by law. In connection with this payment, the Company shall issue a Form W-2 in the regular course
of business.

 

(c)
Provided Executive is eligible for and timely
elects continuation of group health benefits (and, if applicable, eligible dependents) under Section 4980B of the Internal Revenue
Code, or any other comparable federal, state or local law (“COBRA”), for each month that such coverage is in effect,
except as otherwise provided below, up to a maximum of three (3) months, the Company will pay Executive an amount calculated so
that the net amount of such payment, after all required withholding, is equal to the monthly premium associated with such continuation
of benefits, and the net amount of such payment shall be withheld and applied to Executive’s premium. Such payments shall
be terminated as of the end of the month in which Executive’s COBRA coverage terminates for any reason permitted by COBRA,
and shall not apply to the COBRA coverage of any of Executive’s dependents who incur a second qualifying event during the
period of Executive’s coverage

 

    	 	 	 

     

    

 

(d)
Notwithstanding any contrary provision in any of the Company’s equity plans, or any equity grant agreement (the “Award
Documents”), any of Executive’s unvested outstanding Company option grants, (“Company Options”)
shall fully vest as of the Separation Date.

 

(e)
Executive acknowledges and agrees that any Company Options that were originally intended to constitute “incentive stock
options” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) (the “Option”)
shall cease to be “incentive stock options” upon the three (3) month anniversary of the Separation Date pursuant to
the Code; provided, however, that any such Options may cease to be “incentive stock options” sooner as more fully
set forth herein in Exhibit A hereto.

 

3.
Accrued Benefits.

 

(a)
Whether or not Executive chooses to sign this
Separation Agreement, Executive will be entitled to receive the following Accrued Benefits as defined in Section 6(a)(i) of the
Employment Agreement:

 

(i)
Unpaid Base Salary accrued up to the Separation
Date;

 

(ii)
A lump-sum payment, less applicable withholdings
and deductions, that represents the value of Executive’s accrued unused vacation, if any;

 

(iii)
Vested benefits under any Company retirement,
deferred compensation plan or equity plan; and

 

(iv)
COBRA coverage continuation rights under any
Company health care plan, in accordance with the terms of such plans and applicable law.

 

(b)
Executive will also be entitled to any rights
to contribution, advancement of expenses, defense or indemnification Executive may have under the Company’s Articles of
Incorporation or Bylaws, as applicable, or as provided under applicable law; provided, however, that the foregoing shall not provide
for any right to indemnification or advancement for any expenses or liabilities incurred by Executive, including, but not limited
to any attorneys’ fees, amounts paid in settlement and any related costs, arising out of or resulting from any litigation
matters settled or otherwise resolved by Executive without the Company’s consent.

 

4.
No Other Payments or Benefits.
Executive acknowledges and agrees that, other than the payments and benefits expressly set forth in this Separation Agreement,
Executive has received all compensation to which Executive is entitled from the Company, and Executive is not entitled to any
other payments or benefits from the Company. Other than as set forth in this Separation Agreement, after the Separation Date,
Executive shall not receive any base salary, annual bonus, short term or long-term incentive award, welfare, retirement, perquisite,
fringe benefit or other benefit plan coverage or coverage under any other practice, policy or program as may be in effect from
time to time, applying to senior officers or other employees of the Company.

 

    	 	2	 

     

    

 

5.
Agreement Not To Solicit Employees. Executive
hereby reaffirms that, pursuant to the first sentence of Section 4 of the Employment Agreement, until the first anniversary of
the Separation Date, Executive shall not, for herself or any third party, directly or indirectly, employ or solicit for employment
or recommend for employment any person employed by the Company or any Related Company. The first sentence of Section 4 of the
Employment Agreement is hereby incorporated into this Separation Agreement by this reference, so that a breach by Executive of
said Section 4 shall also constitute a breach of this Separation Agreement. For avoidance of doubt, Executive’s obligation
not to compete with the Company pursuant to the second sentence of Section 4 of the Employment Agreement shall terminate on the
Separation Date.

 

6.
Non-Disparagement.
Executive agrees that Executive will not, and will not encourage or induce others to, make, publish or communicate to any person
or entity or in any public forum any defamatory or disparaging remarks, comments or statements concerning any of the Company,
its subsidiaries, affiliates or shareholders or any of their respective past, present or future directors, officers, employees,
agents, shareholders or members or any of their respective successors and assigns (collectively, the “Company Entities and
Persons”). The Company may, at its option, issue an internal and an external announcement regarding Executive’s termination
stating that Executive has separated from employment with the Company for personal reasons. If the Company receives any external
inquiry regarding Executive’s employment history at the Company, the Company will respond to the inquiry by providing Executive’s
dates of employment, Executive’s job title and that Executive separated for personal reasons. Nothing in this Separation
Agreement is intended to or shall prevent any person from providing, or limiting testimony in response to a valid subpoena, court
order, regulatory request or other judicial, administrative or legal process or otherwise as required by law. Executive agrees
that Executive will notify the Company in writing as promptly as practicable after receiving any request for testimony or information
in response to a subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as
required by law, regarding the anticipated testimony or information to be provided and at least ten (10) days prior to providing
such testimony or information (or, if such notice is not possible under the circumstances, with as much prior notice as is possible).

 

7.
Cooperation.
Beginning on the Separation Date and for twelve (12) months thereafter, Executive agrees that Executive will reasonably cooperate
with and assist the Company, its subsidiaries and affiliates, and any of their respective officers, directors, shareholders or
employees: (A) concerning requests for information about the business of the Company or its subsidiaries or affiliates or Executive’s
involvement and participation therein (including but not limited to requests and subpoenas to provide information or testimony);
(B) in connection with any investigation or review by the Company or any federal, state or local regulatory, quasi-regulatory
or self-governing authority as any such investigation or review relates to events or occurrences that transpired while Executive
were employed by the Company; and (C) with respect to transition and succession matters. Executive’s cooperation shall include,
but not be limited to (taking into account Executive’s personal and professional obligations, including those to any new
employer or entity to which Executive provide services), being available to meet and speak with officers or employees of the Company
and/or the Company’s counsel at reasonable times and locations, executing accurate and truthful documents and taking such
other actions as may reasonably be requested by the Company and/or the Company’s counsel to effectuate the foregoing. Executive
shall be entitled to reimbursement from the Company, upon receipt by the Company of suitable documentation, for reasonable and
necessary travel and other expenses which Executive may incur on such matters at the specific request of the Company and as approved
by the Company in advance and in accordance with its policies and procedures established from time to time.

 

    	 	3	 

     

    

 

8.
Company Property; Certain Transition
Matters; Confidentiality.

 

(a)
On or prior to the Separation Date, Executive
will return to the Company and all Related Companies all equipment and other property belonging to the Company and Related Companies,
and all originals and copies or Confidential Information (in any and all media and formats, and including any document or other
item containing Confidential Information) in Executive’s possession or control, and all of the following (in any and all
media and formats, and whether or not constituting or containing Confidential Information) in Executive’s possession or
control: (i) lists and sources of customers; (ii) proposals or drafts of proposals for any research grant, research or development
project or program, marketing plan, licensing arrangement, or other arrangement with any third party; (iii) reports, job or laboratory
notes, specifications, and drawings pertaining to the research, development, products, patents, and technology of the Company
and any Related Companies; and (iv) any and all inventions or intellectual property developed by Executive during the course of
employment.

 

(b)
From and after the Separation Date, Executive
will not represent (or purport to represent) the Company or any of its affiliates in any capacity to any person or entity, or
enter into (or purport to enter into) any transactions, agreements or understandings on behalf of the Company or any of its affiliates
with any person or entity.

 

(c)
Executive hereby reaffirms her obligations pursuant
to Section 5(c) of the Employment Agreement with respect to Confidential Information, as defined therein. Section 5(c) of the
Employment Agreement is hereby incorporated into this Separation Agreement by this reference, so that a breach by Executive of
said Section 5(c) shall also constitute a breach of this Separation Agreement.

 

(d)
Notwithstanding the foregoing, in accordance
with the Defend Trade Secrets Act of 2016, Executive is hereby notified that Executive will not be held criminally or civilly
liable under any federal or state trade secret law for the disclosure of a trade secret that: (i) is made (A) in confidence to
a federal, state or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose
of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document that is filed under
seal in a lawsuit or other proceeding. If Executive files a lawsuit for retaliation by the Company for reporting a suspected violation
of law, Executive may disclose the Company’s trade secrets to Executive’s attorney and use the trade secret information
in the court proceeding if Executive (i) files any document containing the trade secret under seal; and (ii) does not disclose
the trade secret, except pursuant to court order.

 

    	 	4	 

     

    

 

9.
Taxes.
The parties acknowledge and agree that: the form and timing of the Separation Agreement Payments and Benefits to be provided pursuant
to this Agreement are intended to be exempt from or to comply with requirements of Section 409A of the Internal Revenue Code of
1986, as amended, and applicable Treasury Regulations thereunder (“Section 409A”), including the requirement for a
six-month suspension on payments to “specified employees” as defined in Section 409A that are not otherwise permitted
to be paid within the six-month suspension period. Notwithstanding the foregoing, it is also agreed that Executive has had the
opportunity to seek the advice of independent tax counsel with respect to the potential application of Section 409A to the Separation
Agreement, and is not relying upon the advice of the Company or any person affiliated with the Company with respect thereto. In
no event shall the Company or any person affiliated with the Company have any liability to Executive with respect to any adverse
tax consequences, under Section 409A or otherwise, related to the payment of the Separation Agreement payments and benefits.

 

10.
Release and Covenant Not to
Sue.

 

(a)
Executive agrees that, in consideration of this
Separation Agreement, Executive hereby waives, releases and forever discharges, to the extent permitted by applicable law, any
and all claims, complaints, promises, agreements, controversies, liens, demands, actions, causes of action, obligations, suits,
disputes, judgments, rights, debts, bonds, bills, covenants, contracts, variances, trespasses, executions, damages and liabilities
of any nature whatsoever (collectively “Claims”) which Executive ever had, now has or may have against the (i) Company,
(ii) the Company’s past, present and future subsidiaries, affiliates and shareholders, and (iii) the past, present and future
shareholders, members, directors, officers, agents, employees, attorneys, insurers, predecessors, various benefits committees,
successors and assigns, heirs, executors and personal and legal representatives of the Company and the Company’s past, present
and future subsidiaries, affiliates and shareholders ((i), (ii) and (iii), collectively, the “Released Parties”),
based on or relating to any act, event or omission occurring before Executive executes this Separation Agreement arising out of,
during or relating to Executive’s employment or services with the Company or the cessation of such employment or services,
except for claims relating to the enforcement of the Company’s obligations under this Separation Agreement or as provided
below. This waiver and release includes, but is not limited to, any claims which could be asserted now or in the future, under:
common law, including, but not limited to, breach of express or implied duties, wrongful termination, retaliation, defamation,
or violation of public policy; any policies, practices, or procedures of the Company; any federal or state statutes or regulations
including, but not limited to, Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. § 2000e et seq., the
Civil Rights Act of 1866 and 1871, the Age Discrimination in Employment Act (“ADEA”), as amended, 29 U.S.C. §
621 et seq., the Americans With Disabilities Act, 42 U.S.C. §12101 et seq., the Employee Retirement Income
Security Act (“ERISA”), 29 U.S.C. § 41001 et seq. (excluding those rights relating exclusively to employee
pension benefits as governed by ERISA), the Family and Medical Leave Act, 29 U.S.C. §2601 et. seq., the California Fair Employment
and Housing Act, the California Family Rights Act, the California Labor Code; any contract of employment, express or implied;
and any provision of any other law, common or statutory, of the United States, New York, or any applicable state. For the purpose
of implementing a full and complete release, Executive understands and agrees that this Separation Agreement is intended to waive
and release all claims, if any, which Executive may have and which Executive may not now know or suspect to exist in Executive’s
favor against any of the Released Parties and this Separation Agreement extinguishes those claims.

 

    	 	5	 

     

    

 

Without
limiting the generality of the foregoing, Executive expressly waives any and all rights under California Civil Code § 1542
which provides:

 

A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER
FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT
WITH THE DEBTOR OR RELEASING PARTY.

 

(b)
By signing this Separation Agreement, Executive
represents that Executive has not and will not in the future commence any action or proceeding arising out of the Claims described
in Section 10(a), and that Executive will not seek or be entitled to any award of legal or equitable relief in any such action
or proceeding that may be commenced on Executive’s behalf. The provisions of this Section 10(b) constitute a “covenant
not to sue.” A “covenant not to sue” is a legal term which means Executive promises not to file a lawsuit in
court. It is different from the Release of Claims contained in Section 10(a) above. Besides waiving and releasing Claims covered
by Section 10(a), Executive further agrees never to sue any Released Party in any forum for any reason covered by the release
of Claims. Notwithstanding this covenant not to sue, Executive may bring a Claim against the Company to enforce this Separation
Agreement or, to the extent permitted under the law, to challenge the validity of this Separation Agreement under the ADEA. If
Executive sues a Released Party in violation of this Separation Agreement, Executive shall be liable to the Released Party for
its reasonable attorneys’ fees and other litigation costs incurred in defending against Executive’s suit. Alternatively,
if Executive sues a Released Party in violation of this Separation Agreement, the Company can require Executive to return all
but One Thousand Dollars ($1,000.00) of the payment described in Section 2.

 

11.
Release Exclusions/Additional Rights.
Nothing in the Release above or any other part of this Separation Agreement shall: (i) affect any rights of defense or indemnification,
or to be held harmless, or any coverage under directors and officers liability insurance or any other insurance or rights or claims
of contribution or advancement of expenses that Executive has; (ii) waive any rights or claims that Executive may have to the
extent that such rights or claims are based upon events occurring more than seven days after the date Executive executed this
Agreement; (iii) waive, release or otherwise discharge any other claim or cause of action that cannot legally be waived; or (iv)
interfere with Executive’s right to file a charge or cooperate with, provide information to, or participate in an investigation
or proceeding conducted by, the Equal Employment Opportunity Commission, the California Department of Fair Employment and Housing,
or any other federal or state regulatory or law enforcement agency. Executive nonetheless acknowledge and agree that any Claims
for personal relief in connection with such a charge or investigation (such as reinstatement or monetary damages) would be and
hereby are barred. Executive may, however, receive money from the Securities & Exchange Commission (“SEC”) as
a reward for providing information to that agency.

 

    	 	6	 

     

    

 

12.
Time to Consider, Consult With Counsel and
Revoke.

 

(a)
The Company is presenting Executive with this Separation Agreement on January 4, 2019 and Executive has until close of business
on January 25, 2019 to consider it. Executive acknowledge that Executive has been given at least twenty-one (21) days to consider
this Separation Agreement before signing it, and agrees that any changes made to the terms of this Separation Agreement
shall not restart the twenty-one (21) day period.

 

(b)
Executive acknowledges that Executive has been
advised by the Company, in writing, to consult an attorney with respect to this Separation Agreement before signing it.

 

Executive
has the right to revoke this Separation Agreement after signing it by written notice to the Company sent by reputable overnight
courier or email not more than seven (7) days after the date of Executive’s execution of this Separation Agreement. Notice
of revocation should be addressed to OncoCyte Corporation, 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501, ATTN: VP, Human
Resources, Tracey Erwin, or if by email, addressed to terwin@biotimeinc.com. If Executive chooses to revoke this Separation Agreement,
it shall be null and void and without limiting the generality of the foregoing, Executive shall no longer be entitled to the pay
and benefits under Section 2 or any other Section of this Separation Agreement other than the Accrued Benefits described in Section
3. Executive expressly acknowledges that the payments and benefits described in Section 2 represent amounts to which she has no
legal entitlement unless she executes, and does not revoke, this Separation Agreement.

 

13.
Enforcement.
If any provision of this Separation Agreement is held by a court of competent jurisdiction to be illegal, void or unenforceable,
such provision shall have no effect; however, the remaining provisions shall be enforced to the maximum extent possible. Further,
if a court should determine that any portion of this Separation Agreement is overbroad or unreasonable, such provision shall be
given effect to the maximum extent possible by narrowing or enforcing in part that aspect of the provision found overbroad or
unreasonable. In addition, Executive agrees that Executive’s knowing failure to return Company property that relates to
the maintenance of security of the Company Entities and Persons shall entitle the Company to injunctive and other equitable relief.

 

14.
No Admission.
This Separation Agreement is not intended, and shall not be construed, as an admission that either Executive or the Company Entities
and Persons have violated any federal, state or local law (statutory or decisional), ordinance or regulation, breached any contract
or committed any wrong whatsoever.

 

15.
Successors.
This Separation Agreement is binding upon, and shall inure to the benefit of, the parties and their respective heirs, executors,
administrators, successors and assigns.

 

16.
Resolution of Disputes; Choice
of Law.

 

(a)
This Separation Agreement shall be construed and enforced in accordance with the laws of the State of California without regard
to the principles of conflicts of law.

 

(b)
All suits, actions or proceedings arising out of or relating to this Separation Agreement shall be brought in a state or federal
court located in San Francisco County, California, which courts shall be the exclusive forum for all such suits, actions or proceedings.
Executive and the Company hereby waive any objection which either of Executive may now or hereafter have to the laying of venue
in any such court, including any claim based on the doctrine of forum non conveniens or any similar doctrine, for any such suit,
action or proceeding. Executive and the Company each hereby irrevocably consent and submit to the jurisdiction of the federal
and state courts located in San Francisco County, California for the purposes of any suit,
action or proceeding arising out of relating to this Separation Agreement. If any action is necessary to enforce the terms of
this Separation Agreement, the substantially prevailing party will be entitled to reasonable attorneys’ fees, costs and
expenses in addition to any other relief to which such prevailing party may be entitled

 

    	 	7	 

     

    

 

(c)
EXECUTIVE AND THE COMPANY EACH HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING UNDER THIS
SEPARATION AGREEMENT or related in any way to Executive’s employment and/or to the
termination of Executive’s employment AND AGREE THAT ANY SUCH SUIT, ACTION OR PROCEEDING SHALL BE TRIED BEFORE A
COURT AND NOT BEFORE A JURY.

 

(d)
If the waiver of a trial by jury in paragraph (c) of this Section 16 is ineffective or unenforceable, the Company and Executive
agree that all suits, actions or proceedings arising under this Separation Agreement or related in any way to Executive’s
employment and/or to the termination of Executive’s employment brought or heard in a California state court shall be resolved
without a jury, pursuant to California Code of Civil Procedure Section 638 et seq, before a mutually acceptable referee
(who shall be a retired judge). The Company and Executive shall not seek to appoint a referee that may be disqualified pursuant
to California Code of Civil Procedure Section 641 or 641.2 without the prior written consent of all parties. If the parties are
unable to agree upon a referee within ten (10) calendar days after one party serves a written notice of intent for judicial reference
upon the other party or parties, then the referee will be selected by the court in accordance with California Code of Civil Procedure
Section 640(b). Such proceeding shall be conducted in the City and County of San Francisco, California, in accordance with the
California Code of Civil Procedure, the Rules of Court, and California Evidence Code, except as otherwise specifically agreed
by the parties and approved by the referee. In the event Claims are to be resolved by judicial reference, either party may seek
from the court any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the
fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.

 

(e)
Entire Agreement. Executive acknowledges that this Separation Agreement constitutes the
complete understanding between the Company and Executive regarding its subject matter and supersedes any and all agreements, understandings,
and discussions, whether written or oral, between Executive and any of the Company Entities and Persons. No other promises or
agreements shall be binding on the Company unless in writing and signed by both the Company and Executive after the date of this
Separation Agreement. This Separation Agreement shall be construed as though both parties had participated equally in its drafting,
and shall not be construed against either party as the drafting party.

 

17.
Effective Date. Executive may accept this
Separation Agreement by signing it and returning it to OncoCyte Corporation, 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501,
ATTN: VP, Human Resources, Tracey Erwin or if by email, addressed to twerin@biotimeinc.com,
not later than the twenty-first (21st) day after the Separation Agreement is provided to Executive (which is close of business
on January 25, 2019 as described in Section 12(a) above). The Effective Date of this Separation Agreement shall be the date after
the 21-day revocation period expires. In the event Executive does not accept this Separation Agreement as set forth in this Section
17, this Separation Agreement, including but not limited to, the obligation of the Company hereunder to provide the payments and
other benefits under this Separation Agreement, shall be deemed automatically null and void.

 

18.
Headings.
The headings used herein are for the convenience of reference only, do not constitute part of this Separation Agreement and shall
not be deemed to limit or otherwise affect any of the provisions of this Separation Agreement.

 

19.
Counterparts.
This Separation Agreement may be executed in one or more counterparts, including emailed or telecopied facsimiles, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

[Signature
Page to the Separation Agreement Follows]

 

    	 	8	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Separation Agreement as of the dates set forth below.

 

EXECUTIVE

 

	/s/
    Kristine     Mechem	 	Date:
    January 21, 2019
	Kristine
    Mecham	 	 

 

OncoCyte
Corporation

 

	By:
    	/s/
    William     Annett 	 	Date:
    January 22, 2019
	 	William Annett	 	 
	 	Chief Executive
    Officer	 	 

 

[Signature
Page to the Separation Agreement]

 

    	 	9	 

     

    

 

Exhibit
A

 

CONSENT
TO AMENDMENT OF INCENTIVE STOCK OPTIONS

 

To
be signed and delivered to OncoCyte Corporation, on or before January 25, 2019

 

I
am a holder of outstanding stock options (the “Options”) to purchase shares of common stock of OncoCyte Corporation,
(the “Company”) that were granted under the Company’s Employee Stock Option Agreement and/or Equity Incentive
Plan (collectively, the “Equity Plan”). Pursuant to the terms of the Options, without giving effect to the
Separation Agreement between myself and the Company dated January 4, 2019 (the “Separation Agreement”), the
Options will cease to vest as of the date of my termination of employment or Continuous Service (as defined in the Equity Plan)
with the Company and will remain exercisable for three (3) months thereafter. In connection with the Separation Agreement, the
Company (i) has agreed that, subject to the terms and conditions of the Separation Agreement, my Options shall fully vest on the
Separation Date, and (ii) has agreed, subject to approval of the Company’s Board of Directors, my compliance with my obligations
under the Separation Agreement and under any other agreements or policies of the Company and the terms and conditions of the Separation
Agreement, to extend the post-termination exercise period and to permit me to exercise the vested portion of my Options until
the close of business at the Company’s principal office on January 21, 2020 (the post-termination exercise period, the “Options
Amendment”). The Company may not amend the terms of my Options in a manner that would adversely affect my rights under
such Options without my written consent. I understand that with respect to any portion of my Options that is an “incentive
stock option” (“ISO”) under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”),
the Options Amendment is contingent upon my consent to such amendment.

 

Section
424(h) of the Code provides that if the terms of an ISO are modified, then such modification shall be considered as the granting
of a new option. An extension of the post-termination exercise period of my Options would be deemed a modification and, thus,
the grant of new options. As a result, the Options Amendment would require a new comparison of the exercise price and the current
fair market value of the Company’s common stock and would require my employment status as of such date to determine if the
Options, as amended by the Options Amendment, retain ISO status. Therefore, because I will no longer be an employee of the Company,
any ISOs would fail to be treated as an ISO as a result of the Options Amendment, provided they are not exercised by me within
three (3) months after Separation Date.

 

I
understand that I am under no obligation to consent to the Options Amendment. I have read this consent and have had sufficient
time to review and discuss this matter. I understand that in order for the Options Amendment to be effective, I must properly
execute and return my consent to the Options Amendment in accordance with the “important instructions” below and (2)
I must become a party to the Separation Agreement.

 

I
further understand that this consent is intended as a brief summary of the Options Amendment and, thus, if there is any inconsistency
between the information included in this consent and the terms of the Options (as amended by the Separation Agreement), the terms
of the Options shall govern. I acknowledge that the Options Amendment shall not override any contrary provision in the equity
incentive plan or award agreements under which the Options were granted that would provide for earlier termination of any unexercised
Options regarding a corporate transaction, change in control, or other similar transaction.

 

    	 	10	 

     

    

 

I
acknowledge that neither the Company nor its agents have recommended or influenced my decision to consent to the Options Amendment.
I further acknowledge that I have had the opportunity to seek independent advice regarding this matter from my legal counsel and
tax advisor.

 

After
due consideration of the above, I hereby agree to the Options Amendment. I acknowledge that, for any portion of the Options that
are ISOs, the Options Amendment will cause loss of ISO status if they are not exercised within three (3) months after my Separation
Date.

 

	 	/s/
    Kristine     Mechem 
	 	Kristine
    Mechem
	 	 
	 	January
    21, 2019 
	 	Date
    Signed

 

IMPORTANT
INSTRUCTIONS: In order for this Options Amendments to be effective, you must (1) sign and date this Consent to Amendment of
Incentive Stock Options on or before January 25, 2019 and return it to OncoCyte Corporation, and (2) become a party to
the Separation Agreement. This Consent to Amendment of Incentive Stock Options may be returned by hard copy or by emailing
as a PDF attachment to VP, Human Resources, Tracey Erwin at terwein@biotimeinc.com.

 

    	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]